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Introduction: Despite an initial dramatic response to the epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
gefitinib and erlotinib, the majority of non–small cell lung cancer 
(NSCLC) patients with EGFR-activating mutations develop acquired 
resistance. Therefore, there is an urgent need to elucidate the unknown 
mechanisms and biological behaviors of EGFR TKI–resistant lung 
tumors. We investigated the motility of EGFR TKI–resistant cells, as 
these characteristics are relevant to cancer metastasis.
Methods: Erlotinib-resistant PC-9ER cells were generated from 
PC-9 NSCLC cells, which harbor an EGFR-activating mutation, and 
used in this study. We investigated the involvement of the transform-
ing growth factor beta (TGF-β) pathway in cell motility, and tested 
the effects of erlotinib and TGF-β type I receptor (RI) inhibition on 
cell motility.
Results: PC-9ER cells displayed enhanced motility resulting from 
autocrine activation of the TGF-β pathway. Increased TGF-β2 secre-
tion resulting from TGF-β2 up-regulation at the transcriptional level 
was suggested to be responsible for the phosphorylation of Smad2 
and the subsequently elevated transcriptional regulatory activity 
in PC-9ER cells. The motility of PC-9ER cells was suppressed by 
treatment with either the TGF-βRI inhibitor LY364947 or erlotinib, 
and greater suppression was observed when used in combination. 
LY364947 or erlotinib exerted no growth-inhibitory effects, suggest-
ing that motility and growth are driven by different signaling path-
ways in PC-9ER cells.
Conclusions: Our results imply that blockade of the TGF-β  
signaling pathway combined with continuous EGFR TKI treat-
ment will be beneficial in preventing metastasis in patients with 
EGFR TKI–resistant NSCLC without the EGFR T790M resistance 
mutation.
Key Words: Epidermal growth factor receptor tyrosine kinase 
inhibitors resistance, Erlotinib, Motility, Transforming growth factor 
beta signaling, Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 259-269)
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have been 
demonstrated to be effective in non–small-cell lung can-
cer (NSCLC) patients with EGFR-activating mutations.1–6 
However, the majority of responders eventually develop 
acquired resistance to EGFR TKIs.3 Although studies have 
investigated the cause of acquired resistance to EGFR TKIs,7–14 
the characteristics of EGFR TKI–resistant tumors such as cell 
motility that play a pivotal role in the process of meta stasis 
have been poorly investigated.
Recent studies suggested that both genetic alterations 
within cancer cells7–9,12,14 and the activation of the tumor 
microenvironment such as the induction of the epithelial-
mesenchymal transition (EMT) could confer resistance to 
EGFR TKIs.15,16 EMT is known to be induced by activation 
of the transforming growth factor beta (TGF-β) pathway, 
which plays an important role in tumor invasiveness and 
metastasis by directly promoting the motility and/or migratory 
ability of various types of cancers including lung cancer.17  
TGF-β ligands bind and activate the TGF-β receptor complex 
composed of the type II (TGF-βRII) and type I subunits 
(TGF-βRI), which phosphorylate Smad2 and Smad3. Activated 
Smad2/3 forms transcriptional complexes with Smad4 and 
other transcriptional factors and regulates the transcription of 
genes associated with tumor-promoting effects.17 It has been 
reported that the high expression level of TGF-β in several 
tumors correlates with tumor progression and metastasis.18 
TGF-β1 expression was reported to be significantly higher 
in NSCLC patients with lymph node metastasis than in those 
without lymph node metastasis.19 It has also been reported that 
TGF-β1 expression levels in patients with stage III NSCLC 
are significantly higher than those in patients with stage I 
and II NSCLC, and the overall survival of patients with high 
TGF-β1 levels was significantly shorter than that of patients 
with low TGF-β1 levels.19 Blockade of TGF-β signaling by 
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TGF-βRI inhibitors or soluble TGF-β receptor antagonists 
decreased tumor invasion and migration in preclinical 
models,20,21 providing a rationale for a therapeutic approach to 
prevent metastasis based on the inhibition of TGF-β signaling. 
EGFR TKI treatment has also been suggested to inhibit 
TGF-β–induced cell motility,22 which leads to the hypothesis 
that the combination of EGFR TKIs and TGF-β inhibitors may 
be more beneficial for preventing metastasis. In this study, we 
investigated the involvement of the TGF-β pathway in the motility 
of erlotinib-resistant NSCLC cells and the effects of erlotinib and 
TGF-βRI inhibition on erlotinib-resistant NSCLC cells.
MATERIALS AND METHODS
Cell Culture and Reagents
The human NSCLC (adenocarcinoma) cell line PC-9, 
which harbors an EGFR-activating mutation (exon 19 deletion, 
E746-A750del), was provided by Dr. Koizumi (National Cancer 
Center Hospital, Tokyo, Japan). The human NSCLC (squa-
mous cell carcinoma) cell line EBC1, which is characterized 
by MET proto-oncogene amplification, was purchased from the 
Japanese Collection of Research Bioresources (Osaka, Japan). 
All cell lines used in this study were maintained in RPMI1640 
(Invitrogen, Carlsbad, CA) supplemented with 10% heat- 
inactivated fetal bovine serum (FBS; Invitrogen) in humidi-
fied air containing 5% carbon dioxide at 37°C. Erlotinib was 
supplied by F. Hoffmann-La Roche (Basel, Switzerland). 
Gefitinib (Tocris Bioscience, Ellisville, MO), LY364947 
(Sigma, St. Louis, MO), and PHA-665752 (Tocris Bioscience) 
were purchased from the indicated companies. TGF-β2 was 
purchased from R & D Systems (Minneapolis, MN).
Establishment of the Erlotinib-
Resistant Cell Lines
 PC-9 cells were exposed to increasing concentrations of 
erlotinib (0.1–10 μmol/l) for 15 months. Several clones were 
subcloned by limiting dilution, and we selected two clones 
(PC-9ER1 and PC-9ER4) for this study after we confirmed 
that they acquired resistance to erlotinib.
In Vitro Growth Inhibition Assay
The growth-inhibitory effects of erlotinib, gefitinib, 
LY364947, and PHA-665752 were examined using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) 
assay as described previously.23 In brief, a 180-µl volume of 
an exponentially growing cell suspension was seeded into each 
well of a 96-well plate (Corning Coaster, Cambridge, MA) 
containing 10% FBS medium and incubated for 24 hours. 
The cells were exposed to 20 µl of each inhibitor at various 
concentrations and further cultured at 37°C in a humidi-
fied atmosphere for 72 hours. After the culture period, 20 µl 
of MTT solution (5 mg/ml in phosphate-buffered saline) was 
added to each well, and the plates were incubated for 4 hours at 
37°C. After centrifuging the plates, the medium was aspirated 
from each well, and 200 µl of DMSO was added to each well 
to dissolve the formazan. The growth-inhibitory effect of each 
inhibitor was assessed spectrophotometrically (Model 680 
microplate plate reader; Bio-Rad Laboratories, Hercules, CA).
Immunoblot Analysis
The cultured cells were washed twice with ice-cold 
phosphate-buffered saline and lysed in M-PER mammalian 
protein extraction reagent with an EDTA-free Halt prote-
ase inhibitor cocktail and Halt phosphatase inhibitor cock-
tail (Pierce Chemical Co., Rockford, IL). Equal amounts of 
protein (20 µg) in whole-cell lysate (as measured by using 
the BCA protein assay reagent [Pierce Chemical Co.]) were 
separated by 8% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes 
(Bio-Rad). Membranes were blocked with 5% skim milk or 
5% bovine serum albumin (BSA) in Tris-buffered saline-
Tween 20 (TBST) for 1 hour at room temperature and then 
incubated overnight with primary antibodies in TBST contain-
ing 5% skim milk or 5% BSA at 4°C. After the membranes 
were washed thrice with TBST, they were incubated with sec-
ondary antibodies conjugated to horseradish peroxidase for 1 
hour at room temperature and then subjected to three washes 
with TBST. Immunoreactive bands were visualized using the 
SuperSignal West Pico Chemiluminescent Substrate (Pierce 
Chemical Co.), and the images were captured using the 
ImageQuant LAS4000 system (GE Healthcare, Piscataway, 
NJ). Densitometric analysis was performed using ImageQuant 
TL software (GE Healthcare). The antibodies used for this 
analysis are listed in Supplementary Table S1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A361).
Wound-Closure Assay
Cells (3 × 105 cells/well) were seeded into 6-well plates 
(Corning Coaster). Cell motility was determined by measur-
ing the movement of cells to close an artificial wound cre-
ated with a 200-µL pipette tip (time point 0 hour) when the 
cells reached confluency. Afterward, the cells were washed 
with FBS-free medium and then incubated in fresh 1% FBS 
medium with or without inhibitors. Wound closure was moni-
tored by microscopy at the indicated time points.
Transwell Assay
The transwell assay was performed according to the 
method of Bakin et al.24 Cells (1.5 × 105 cells/well) were seeded 
in 0.1% FBS medium in the upper chamber of a 5-μm pore 
filter unit (Corning Coaster) and incubated in 1% FBS medium 
with or without the inhibitors. Twenty-four hours later, cells 
that had migrated through pores and reattached to the bot-
tom of lower chamber were trypsinized, and the cell number 
was counted using a Coulter Z1 particle counter (Beckman 
Coulter, Brea, CA).
Luciferase Assay
 Cells (5 × 104 cells/well) were seeded in 24-well plates 
(Corning Coaster). After incubation for 48 hours, cells were 
transfected with 1 µg/well of either p(CAGA)
12
-Lux or p3TP-
Lux Smad-dependent reporter plasmid containing Firefly 
luciferase using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. Transfection efficiency 
was normalized by cotransfecting 16 ng/well of pRL-CMV 
(Promega, Madison, WI), which contains the cytomegalovirus 
enhancer, to provide stably high expression of Renilla 
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reniformis luciferase. The next day, cells were incubated in 
RPMI1640 with or without the inhibitors. After 16 or 48 hours, 
cells were lysed in Reporter Lysis Buffer (Promega), and 
luciferase activity was assessed using the Dual-Glo luciferase 
assay system (Promega) with an ARVO MX luminometer 
(PerkinElmer, Norwalk, CT).
TGF-β1, TGF-β2, and TGF-β3 Enzyme-Linked  
Immunosorbent Assay
Cells (3 × 105 cells/well) were seeded in 6-well plates and 
incubated for 30 hours. Then, the cells were incubated in freshly 
replaced FBS-free medium for an additional 60 hours, and the 
supernatant culture medium was collected and centrifuged. To 
quantify the amount of TGF-β1, TGF-β2 and TGF-β3 in the 
conditioned medium, a human TGF-β1 Quantikine ELISA kit, 
a human TGF-β2 Quantikine ELISA kit and a human TGF-
β3 DuoSet kit were used, respectively. These ELISA kits were 
purchased from R&D Systems. Next, acid activation was 
performed according to the manufacturer’s instructions. The 
obtained raw data were normalized by cell number.
Quantitative Real-Time 
Polymerase Chain Reaction
Cells (1 × 106 cells/dish) were seeded into 60-mm dishes 
(Corning Coaster) and incubated for 30 hours. After the 
cell-culture medium was replaced with FBS-free medium, 
cells were incubated for 12 hours in FBS-free medium. Total 
RNAs were isolated using an RNeasy Mini kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instruc-
tions. cDNA template synthesis was performed with total RNA 
(1 μg), Oligo(dT)
12–18
 Primer (Invitrogen), and an Omniscript 
RT Kit (QIAGEN) according to the manufacturer’s instruc-
tions. Quantitative real-time-polymerase chain reaction 
(PCR) amplification and detection were performed on the 
StepOnePlus Real time PCR system (Applied Biosystems, 
Foster City, CA) using SYBR Premix Ex TaqII (Tli RNaseH 
Plus) (TAKARA BIO, Shiga, Japan) and Perfect Real Time 
PCR primers for each gene (TAKARA BIO).
Small Interfering RNA Transfection
Cells (3 × 105 cells/well) were seeded into 6-well plates. 
After incubation for 48 hours, cells were transfected with 250 
pmol/well of small interfering RNA (siRNA) targeting SMAD2 
(VHS41107) and TGFB2 (HSS110687) or scramble control 
siRNA (Stealth RNAi Negative Control Low GC Duplex) 
using Lipofectamine 2000 according to the manufacturer’s 
instructions. These siRNAs were purchased from Invitrogen.
RESULTS
EGFR TKI-Resistant PC-9ER Cells 
Exhibit Enhanced Motility
PC-9ER1 and PC-9ER4 cells generated for this study 
displayed resistance to erlotinib with approximately 100-fold 
higher 50% inhibitory concentration (IC
50
) values than PC-9 
cells (Fig. 1A, Supplementary Table S2, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A361) and also dis-
played resistance to gefitinib (Fig. 1A, Supplementary Table 
S2, Supplemental Digital Content 1, http://links.lww.com/
JTO/A361). Acquired resistance to EGFR TKIs in PC-9ER 
cells was not caused by previously reported mechanisms, 
such as the EGFR T790M mutation (Supplementary Fig. 
S1A, Supplemental Digital Content 2, http://links.lww.com/
JTO/A362),7 KRAS mutations around codons 12, 13, and 
61 (Supplementary Fig. S1A, Supplemental Digital Content 
2, http://links.lww.com/JTO/A362),8 MET amplification 
(Supplementary Fig. S4),9 phosphatase and tensin homolog 
(PTEN) loss (Supplementary Fig. S1B, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A362),12 IGF-1Rβ acti-
vation (data not shown),10 or hepatocyte growth factor (HGF) 
overexpression (data not shown).11 In PC-9ER cells, erlotinib 
suppressed the phosphorylation of EGFR and extracellular 
signal-regulated kinases 1/2 (ERK 1/2), but not that of Akt and 
S6 (Supplementary Fig. S1B, Supplemental Digital Content 
2, http://links.lww.com/JTO/A362). These results suggest that 
persistent activation of phosphatidylinositol-3-kinase (PI3K)/
v-akt murine thymoma viral oncogene homolog (Akt) path-
way may confer resistance to EGFR TKIs in PC-9ER cells.
PC-9ER cells underwent a distinct morphological 
change to an epithelial cobblestone-like phenotype, whereas 
PC-9 parental cells exhibited an elongated mesenchymal-
like morphology (Fig. 1B). We then compared the motil-
ity of PC-9 and PC-9ER cells and found that PC-9ER cells 
migrated faster to close the wound than PC-9 cells did, and 
enhanced cell migration was also confirmed by the transwell 
assay (Fig. 1C). Enhanced motility is frequently observed in 
mesenchymal cells that have undergone an EMT.25 However, 
PC-9ER cells lost vimentin (mesenchymal marker) expression 
but retained E-cadherin (epithelial marker) expression, thus 
suggesting that the enhanced cell motility of PC-9ER cells is 
independent of EMT (Supplementary Fig. S1B, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A362).
TGF-β/Smad Pathway is 
Activated in PC-9ER Cells
Next, we examined the status of the TGF-β/Smad 
pathway, which plays an important role in cell motility and 
migration. Enzyme-linked immunosorbent assay (ELISA) 
was performed to quantify the production of TGF-β ligands 
secreted in an autocrine manner in the culture medium. 
PC-9ER cells were found to secret significantly higher amounts 
of TGF-β2, but not TGF-β1 or TGF-β3, than PC-9 cells did 
(Fig. 2A; the amount of TGF-β3 was below the detection limit 
in all cell lines). TGF-β2 mRNA levels in PC-9ER cells were 
approximately 10-fold higher than those in PC-9 cells 
(Fig. 2B), whereas the difference in TGF-β1 mRNA levels 
was not statistically significant. These results indicated 
that the higher levels of TGF-β2 secretion observed in 
PC-9ER cells were caused by an increase in TGF-β2 mRNA 
expression. Massive phosphorylation of Smad2, which is 
a downstream effector of the TGF-β pathway, was detected 
in PC-9ER cells (Fig. 2C). Subsequent Smad-mediated 
transcriptional regulatory activity was also significantly 
enhanced in PC-9ER cells according to a transcriptional 
reporter assay (Fig. 2C, Supplementary Fig. 2A, Supple-
mental Digital Content 3, http://links.lww.com/JTO/A363). 
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These results indicate that the TGF-β/Smad pathway is 
activated in PC-9ER cells.
Silencing of TGF-β2 or Smad2 Suppresses 
the Enhanced Motility of PC-9ER Cells
To confirm the involvement of the TGF-β/Smad path-
way in the enhanced motility of PC-9ER cells, we depleted 
TGF-β2 and Smad2 with specific siRNAs targeting each gene. 
Smad2 siRNA completely suppressed Smad2 expression and 
Smad2 phosphorylation in PC-9ER cells (Fig. 3A). TGF-β2-
siRNA significantly suppressed Smad2 phosphorylation and 
TGF-β2 secretion in PC-9ER cells (Fig. 3A and B). Silencing 
TGF-β2 or Smad2 also attenuated the enhanced motility of 
PC-9ER cells (Fig. 3C), confirming that TGF-β/Smad path-
way activation and the increased secretion of TGF-β2 contrib-
ute to the enhanced motility of PC-9ER cells.
Stimulation of PC-9 Cells with TGF-
β2 Induces an Increase in Motility and 
Activates the TGF-β/Smad Pathway
To further investigate whether the increased secretion 
of TGF-β2 contributed to the enhanced motility of PC-9ER 
FIGURE 1.  Erlotinib-resistant PC-9ER cells exhibit enhanced cell motility. A, PC-9 parental cells and erlotinib-resistant PC-9ER1 
and PC-9ER4 cells were exposed to erlotinib or gefitinib at the indicated concentrations, and the viability of cells was measured 
after 72 hours of treatment by using the MTT assay. B, Phase-contrast microscopy of PC-9 and PC-9ER cells. C, Wound closure 
was monitored 12 hours after scraping (left panel). Cells that migrated through the transwell filter and attached to the bottom 
of the lower chamber were trypsinized and counted 24 hours after cell seeding. The error bars indicate SDs of the mean (right 
panel). MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.
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FIGURE 2.  The TGF-β/Smad signaling pathway is activated in PC-9ER cells. A, Cells were seeded and incubated in 6-well plates 
for 60 hours in FBS-free medium. Conditioned medium was collected, and the total TGF-β1 and TGF-β2 levels were measured 
using enzyme-linked immunosorbent assay. The error bars indicate SDs of the mean. B, The cellular mRNA levels of TGF-β1 
and TGF-β2 were measured using quantitative real-time polymerase chain reaction. The error bars indicate SDs of the mean. 
C, Immunoblot analysis of total Smad2/3, phospho-Smad2, and total Smad4 (left panel). A luciferase assay was performed to 
assess the Smad-mediated transcriptional regulatory activity by using the Smad-dependent reporter p(CAGA)12-Lux. The values 
were normalized relative to the Renilla luciferase activity of a cotransfected pRL-CMV plasmid. The error bars indicate SDs of the 
mean (right panel). TGF, transforming growth factor beta; FBS, fetal bovine serum.
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cells, we examined the effect of TGF-β2 stimulation on the 
motility and TGF-β/Smad pathway activity of PC-9 cells. 
TGF-β2 stimulation increased cell motility and Smad2 
phosphorylation, which were abrogated by the addition of 
LY364947 (TGF-βRI inhibitor) (Fig. 4A and B). Smad-
mediated transcriptional regulatory activity was also 
significantly induced by TGF-β2 stimulation, and it was 
suppressed by LY364947 (Fig. 4C, Supplementary Fig. 
S2B, Supplemental Digital Content 3, http://links.lww.com/
JTO/A363). Surprisingly, erlotinib alone attenuated the cell 
motility induced by TGF-β2, suggesting potential crosstalk 
between the EGFR and TGF-β/Smad pathways (Fig. 4A). 
Indeed, modest erlotinib-induced Smad2 phosphorylation and 
subsequent Smad-mediated transcriptional regulatory activity 
were observed (Fig. 4B and C), which may be a compensatory 
response to EGFR pathway inhibition.
Combined Treatment with Erlotinib 
and LY364947 Abrogates the 
Enhanced Motility of PC-9ER Cells
We next examined combined blockade of the EGFR 
and TGF-β/Smad pathways. LY364947 reduced the motility 
of PC-9ER cells, whereas it had almost no effect on PC-9 
parental cells (Fig. 5A). Erlotinib not only effectively 
abolished the motility of PC-9 cells, but also suppressed the 
motility of PC-9ER cells (Fig. 5A), suggesting that PC-9ER 
cells still retain partial sensitivity to erlotinib in terms of cell 
FIGURE 3.  Depletion of TGF-β2 and Smad2 suppresses the enhanced motility of PC-9ER cells. A, After transfecting  
negative-control, TGF-β2-specific, or Smad2-specific siRNA into the cells, the cells were washed and incubated with FBS-free 
medium for 24 hours. Cell lysates were immunoblotted to detect the indicated proteins. The relative value of each band to the 
control value according to densitometric analysis is indicated. B, After transfecting negative-control or TGF-β2-specific siRNA 
into the cells, the cells were washed and incubated with FBS-free medium for 24 hours. TGF-β2 enzyme-linked immunosorbent 
assay was performed according to the manufacturer’s instructions. *p < 0.05; ***p < 0.001 (Student’s t test). The error bars 
indicate SDs of the mean. C, After transfecting negative-control, TGFB2-specific, or SMAD2-specific siRNA into the cells, the cells 
were washed and incubated with FBS-free medium for 8 hours. Then, a wound was made with a 200-μl pipette tip, and the 
cells were incubated with FBS-free medium for 42 hours. TGF, transforming growth factor beta; siRNA, small interfering RNA; 
FBS, fetal bovine serum.
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motility, and that continuous treatment with erlotinib may 
be beneficial in preventing metastasis even after the failure 
of EGFR TKI monotherapy, especially in the absence of the 
EGFR T790M resistance mutation. Combined treatment 
with erlotinib and LY364947 suppressed the motility of 
PC-9ER cells more effectively than did each treatment alone 
(Fig. 5A). These findings were also confirmed by a transwell 
assay (Fig. 5B). LY364947 abrogated phospho-Smad2 
expression and attenuated phospho-ERK1/2 expression in 
PC-9ER cells (Fig. 5C, Supplementary Fig. S3, Supplemental 
Digital Content 4, http://links.lww.com/JTO/A364). Erlotinib 
also significantly reduced phospho-ERK1/2 expression 
but did not affect phospho-Akt expression in PC-9ER cells 
(Fig. 5C). The combination of the two inhibitors completely 
suppressed the phosphorylation of both ERK1/2 and Smad2 
in PC-9ER cells (Fig. 5C). These results suggest that the 
ERK1/2 pathway is prominently involved in the motility of 
PC-9ER cells. LY364947, either alone or in combination 
with erlotinib, did not suppress the persistent activation of 
the PI3K/Akt pathway, which may confer resistance to EGFR 
TKIs in PC-9ER cells (Fig. 5C), and did not affect the viability 
of PC-9ER cells or their sensitivity to EGFR TKIs (Fig. 5D). 
These results suggest that motility and growth are driven by 
different mechanisms in PC-9ER cells.
DISCUSSION
It is widely known that acquired resistance to EGFR 
TKIs eventually emerges in patients with EGFR-mutant lung 
tumors after treatment,7–14 and it is not surprising when those 
tumors acquire additional biological features simultaneously, 
which may lead to a more aggressive/malignant phenotype. 
In this study, we demonstrated that PC-9ER cells acquired 
enhanced motility as an additional phenotypical and 
biological characteristic when they acquired resistance to 
EGFR TKIs such as erlotinib. Our findings shed light on the 
additional biological changes that occur when tumors become 
resistant to EGFR TKIs. Proposed mechanisms responsible 
for the acquired resistance to erlotinib and the enhanced 
motility of PC-9ER cells are indicated in Supplementary 
Fig. S5 (Supplemental Digital Content 5, http://links.lww.
com/JTO/A365). We showed that PC-9ER cells acquired 
constitutive TGF-β/Smad pathway activation because of an 
increase in TGF-β2 mRNA expression and the subsequent 
increased secretion of TGF-β2 (Fig. 2, Supplementary Fig. 
S5A, Supplemental Digital Content 5, http://links.lww.com/
JTO/A365), which resulted in enhanced cell motility (Fig. 
1C, Supplementary Fig. S5A, Supplemental Digital Content 
5, http://links.lww.com/JTO/A365). This phenomenon is 
consistent with the result that erlotinib treatment induced 
FIGURE 4.  Exogenous TGF-β2 stimula-
tion of PC-9 parental cells. A, PC-9 
cells were grown on 6-well plates to 
100% conf uence, and then a wound 
was made with a 200-μl pipette tip, 
after which the cells were washed with 
FBS-free medium and incubated with 
FBS-free medium with or without TGF-
β2 (10 ng/m;) in the absence or pres-
ence of erlotinib (1 μmol/l), LY364947 
(3 μmol/l), or erlotinib and LY364947 
in combination for 20 h. B, Cells were 
FBS-starved for 16 hours, pretreated 
with erlotinib (1 μmol/l), LY364947 (3 
μmol/l), or erlotinib and LY364947 in 
combination for 3 hours, and stimu-
lated for 1 hour with TGF-β2 (10 ng/
ml). Cell lysates were immunoblotted 
to detect the indicated proteins. C, 
After transfecting the Smad-dependent 
reporter p(CAGA)12-Lux into PC-9 cells, 
the cells were incubated for 16 hours in 
10% FBS medium with or without TGF-
β2 (10 ng/ml) in the absence or pres-
ence of erlotinib (1 μmol/l), LY364947 
(3 μmol/l), or erlotinib and LY364947 in 
combination. The values were normal-
ized relative to the Renilla luciferase 
activity of a cotransfected pRL-CMV 
plasmid. ***p < 0.001 (Student’s t test). 
The error bars indicate SDs of the mean. 
TGF, transforming growth factor beta; 
FBS, fetal bovine serum.
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FIGURE 5.  Combined blockade  
of the EGFR and TGF-β signaling 
pathways. A, Cells were seeded  
and grown to 100% confuence  
followed by scraping with a 200-μl 
pipette tip and incubation for 16 
hours with 1% FBS medium with 
erlotinib (1 μmol/l), LY364947  
(3 μmol/l), or erlotinib and 
LY364947 in combination. B,  
Cells were seeded into transwell 
chambers and incubated with  
1% FBS medium in the absence or 
presence of erlotinib (1 μmol/l), 
LY364947 (3 μmol/l), or erlotinib 
and LY364947 in combination. 
The number of cells that migrated 
through the filter and attached to 
the bottom of the lower chamber 
was counted 24 hours after cell 
seeding. *p < 0.05; **p < 0.01; 
***p < 0.001 (Student’s t test). The 
error bars indicate SDs of the mean. 
C, PC-9 and PC-9ER cells  
were treated with erlotinib  
(1 μmol/l), LY364947 (3 μmol/l),  
or erlotinib and LY364947 in  
combination for 12 hours. Cells 
were lysed, and the indicated  
proteins were detected using  
immunoblotting. D, PC-9ER 
cells were exposed to erlotinib, 
LY364947, or erlotinib and 
LY364947 in combination at the 
indicated concentrations. The 
viability of cells was measured after 
72 hours of treatment by using the 
MTT assay. EGFR, epidermal growth 
factor receptor; TGF, transforming 
growth factor beta; FBS, fetal bovine 
serum; MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium.
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Smad2 phosphorylation in parental PC-9 cells (Figs. 4B 
and 5C, Supplementary Fig. S5B, Supplemental Digital 
Content 5, http://links.lww.com/JTO/A365), suggesting that 
compensatory signaling and crosstalk occur between the EGFR 
and TGF-β/Smad pathways in these cells (Supplementary 
Fig. S5, Supplemental Digital Content 5, http://links.lww.
com/JTO/A365). On the basis of the results of this study, 
we propose a strategy for the combined blockade of the 
EGFR and TGF-β/Smad signaling pathways and a putative 
biological explanation for this phenomenon (Supplementary 
Fig. S5D, Supplemental Digital Content 5, http://links.lww.
com/JTO/A365). There have been several reports regarding 
the crosstalk between EGFR family members and the 
TGF-β pathway. TGF-β1 has been reported to activate EGF 
signaling in hepatocytes by promoting the shedding of EGF-
like ligands and phosphorylation of Src.26 It has also been 
reported that human epidermal growth factor receptor type 
2 (HER2) overexpression in the nontumorigenic mammary 
epithelium is permissive of the ability of TGF-β to induce 
cell motility, and HER2 and TGF-β signaling cooperate 
in the induction of cellular events associated with tumor 
progression.27 Linkage of ERK activation by TGF-β with 
angiogenesis was previously reported.28 Our results indicate 
that Ras-mitogen-activated protein/extracellular signal-
regulated (MEK)-ERK signaling is involved in both the 
EGFR and TGF-β pathways and that this signaling needs to 
be repressed to abrogate the enhanced motility of PC-9ER 
cells (Supplementary Fig. S5D, Supplemental Digital Content 
5, http://links.lww.com/JTO/A365).
EMT is known to play an important role in cell 
motility, migration, and invasion, which potentially lead 
to metastasis.25,29 Cells with a mesenchymal phenotype 
tend to have a greater motility, but this is not a universal 
finding; 4T1 breast cancer cells displayed high metastatic 
properties even though they retained an epithelial phenotype 
according to their EMT marker profile.30 Meanwhile, 67NR 
breast cells exhibiting nonmetastatic properties displayed 
a mesenchymal phenotype based on their EMT marker 
profile.30 These reports suggest that EMT is not the only 
mechanism that promotes cell motility; other mechanisms 
may also play pivotal roles in enhancing the metastatic 
potential of cancer cells.30,31 In our study, PC-9ER cells 
exhibited a more epithelial-like phenotype according to 
their morphology and the presence of EMT markers such as 
vimentin and E-cadherin (Fig. 1B, Supplementary Fig. S1B, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A362), and it is clear that the enhanced motility of PC-9ER 
cells is not caused by EMT, although TGF-β signaling 
activation is the driving force.
It was reported that TGF-β ligand-induced activa-
tion of the TGF-β pathway in erlotinib-resistant NSCLC 
cells (H1650-M3) led to both EMT, resulting in enhanced 
motility, and the development of resistance to erlotinib.32 
However, NCI-H1650 parental cells exhibit intrinsic resis-
tance to EGFR TKIs because of C-terminal deletion of the 
PTEN gene,12,33 and consequently, the biological nature of 
H1650-M3 cells is not necessarily comparable with that of 
PC-9ER cells, which originally harbor an EGFR-activating 
mutation. PC-9ER cells did not exhibit morphological and 
molecular evidence of EMT (Fig. 1B, Supplementary Fig. 
1B, Supplemental Digital Content 2, http://links.lww.com/
JTO/A362), and blockade of TGF-β signaling by LY364947 
did not restore the sensitivity of PC-9ER cells to erlotinib 
(Fig. 5D). TGF-β/Smad signaling pathway activation in 
PC-9ER cells does not confer resistance to erlotinib, and this 
pathway is only involved in enhanced cell motility, unlike the 
H1650-M3 cells reported by Yao et al.32 These two resistance 
models may represent two different possibilities accounting 
for acquired resistance to EGFR TKIs in the clinical setting.
It is noteworthy that TGF-β2 was up-regulated and 
responsible for the subsequent activation of TGF-β/Smad sig-
naling in PC-9ER cells that resulted in enhanced cell motil-
ity instead of TGF-β1, which is the major TGF-β ligand 
and is well known to play a prominent role in TGF-β/Smad 
signaling (Supplementary Fig. S5A, Supplemental Digital 
Content 5, http://links.lww.com/JTO/A365).17 Little has been 
reported on how TGF-β ligands such as TGF-β1, TGF-β2, or 
TGF-β3 play differential roles and their relevance to clinical 
outcome. Tsamandas et al.34 reported that among all TGF-β 
ligands, TGF-β2 seemed to be most involved in tumor pro-
gression and related with a poorer prognosis in patients with 
advanced-stage colon cancer. There has been no report regard-
ing the correlation between TGF-β2 and tumor progression 
and/or metastasis in NSCLC, and this is the first report on the 
involvement of TGF-β2 in the metastatic process in NSCLC. 
The differential roles of TGF-β ligands in lung cancer biology 
and their relationship with EGFR TKI resistance need to be 
further studied.
Reports suggest that continuous treatment with EGFR 
TKIs after disease progression based on Response Evaluation 
Criteria in Solid Tumors criteria is associated with better sur-
vival and that this treatment results in the stabilization and/or 
improvement of symptoms and a reduction in tumor size.35,36 
Moreover, the accelerated progression of disease after discon-
tinuation of EGFR TKIs, termed a disease flare, during the 
washout period has been reported,37 and the use of EGFR TKIs 
after disease progression is under clinical evaluation.38–40 These 
clinical findings seem to support the hypothesis that tumors 
with acquired resistance and/or nonresistant residual tumors 
still rely on EGFR signaling and that blockade of EGFR sig-
naling via continuous treatment with EGFR TKIs may be still 
beneficial. EGFR signaling is also known to play a role in cell 
motility.41,42 In this study, we report an additional rationale for 
continuing the use of EGFR TKIs after disease progression in 
that resistant tumors may retain sensitivity to EGFR TKIs in 
terms of the inhibition of cell motility (Supplementary Fig. 
S5 B, Supplemental Digital Content 5, http://links.lww.com/
JTO/A365). In addition, as demonstrated in this study, the 
enhanced motility of PC-9ER cells was effectively suppressed 
by the combination of erlotinib and LY364947 (Fig. 5A, B, 
Supplementary Fig. S5 D, Supplemental Digital Content 5, 
http://links.lww.com/JTO/A365).
Taken together, these data indicate that combined block-
ade of the EGFR and TGF-β pathways will be beneficial in 
preventing metastasis in patients with EGFR TKI–resistant 
NSCLC, although these results need to be further validated 
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using in vivo models and clinical specimens from patients 
with acquired resistance to EGFR TKIs.
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